Chief Executive Officer
Mr. Boyer is the chief executive officer at SCA Pharmaceuticals. Formerly he was senior vice president and business unit head of the Drug Product Division at AMRI. He joined AMRI in 2014 upon the acquisition of OSO BioPharmaceuticals where he served as president and CEO and was also a member of the Board of Directors. For the past 18 years, his assignments have been focused in contract manufacturing for both pharmaceuticals and biopharmaceuticals, developing experience and expertise for both drug substance and drug product. He holds a B.S. in Chemistry/Physics and an M.S. in Biochemistry.
Mr. Boyer is very active in trade groups and educational institutions that support the pharmaceutical and biopharmaceutical industry. In addition to DCAT, he currently serves on the External Advisory Board for the Department of Chemistry and Biology for the University of New Mexico. He has also been a member of other professional organizations, including the American Association of Pharmaceutical Scientists (AAPS), International Society of Pharmaceutical Engineers (ISPE) and the Parenteral Drug Association (PDA).
Global Director, Sourcing
Eli Lilly & Company
Mr. Sutton is the global director of sourcing for Lilly’s manufacturing and human resources organizations. He has over 25 years experience with Eli Lilly and Company, having held various roles in support of the manufacturing organization including IT, supply chain operations, finance and procurement. He is responsible for developing and implementing the global sourcing strategies for API and dry product manufacturing, facilities management and utilities, as well as health, wellness and benefit programs, recruiting services and learning and development services.
Mr. Sutton has been an active DCAT event participant since 2000 and joined DCAT's Supply Chain Management Committee in 2011. He was appointed chairperson of the Supply Management Committee for 2013-2014 and served on the Board of Directors from 2010-2013.
He holds a B.S. in Management Information Systems from Brigham Young University and an M.B.A. from Indiana State University.
Senior Vice President Business Development
Mr. Magrì previously served as vice president of corporate business development at Infa, Inc. He joined Infa in 2005 as marketing and sales director. Since then, Infa has grown by acquisition to include sites in Italy and Spain and the business has expanded with the addition of a new division focused on contract manufacturing.
Previously, Mr. Magrì served as marketing and sales director at Sicor, which he joined in 2001, and in Teva’s API division, after the acquisition of Sicor in 2003.
His strong track record in the industry also includes previous roles at Archimica/Pro.Bio.Sint. and Fordras.
Mr. Magrì earned his Master’s degree in Chemistry and Pharmaceutical Technology from the University of Milan, Italy.
Stephan Kutzer, Ph.D.
Chief Executive Officer
Stephan brings valuable leadership experience with over 18 years in the pharmaceutical & biotech industry managing large contract services enterprises. Prior to joining Alcami, Dr. Kutzer served as Chief Operating Officer of Lonza’s Pharma & Biotech division which is part of the global chemicals and biotechnology company Lonza Group. Since 2003, he has also served as Chief Operating Officer and/or President of several divisions, including Lonza Custom Manufacturing, Lonza Biopharmaceuticals and Lonza Performance Chemicals. Dr. Kutzer holds a Master’s Degree in Chemical and Process Engineering and a Ph.D. in Engineering Sciences (Chemical Engineering) from the Technical University of Munich, Germany.
Senior Director, Business Development
Gyma Laboratories of America, Inc.
Anita Anderson has been in the generic pharma industry for 20 years, holding various positions in sales and business development. She is currently the Senior Director of Business Development at Gyma Laboratories a position she has held since July 2016.
Ms. Anderson has been actively involved in the DCAT organization, holding positions on various committees, including chairperson of the Science and Scholarship Committee and as a member of the DCAT Advisory Council for the last three years. She serves as chairperson for the Board of Education in her hometown and is a member of the local Rotary Club.
Head - CMO
Dr. Behrens is the Head of the CMO business at Biocon Ltd. At Biocon, Dr. Behrens is driving business development activities for customised APIs (R&D and commercial) and high potent solid dosage forms (R&D and commercial). Prior to this he was Head of Strategic Procurement at Helm AG, which he joined in 2015. At Helm, Dr. Behrens was in charge of outsourcing development and manufacturing services to CMOs and of insourcing products and bringing development projects to support the growth of Helm AG. For the past 16 years, his assignments have been focused in contract manufacturing for both pharmaceuticals and biopharmaceuticals, developing experience and expertise for both drug substance and drug product with a strong focus on global CMO sales. He holds a PhD in Pharmacy.
Dr. Behrens has been an active DCAT event participant since 2009 and joined DCAT's Education Committee in 2011. He served on the Advisory Council from 2013-2016.
Michael Humora, Ph.D.
J-STAR Research Inc.
Mr. Humora is a director at J-STAR Research Inc., a contract chemistry organization serving as an outsourcing partner for the pharmaceutical and biotechnology industries. Previously, he served as the Technical Development Fellow for Chemical Process Research and Development, as well as Principal Investigator and Principal Scientist for Biogen from 2007 through 2015. There he had extensive hands on experience from pre-clinical to commercial API production encompassing process research, process development, process validation, outsourcing and global manufacturing.
He earned his Ph.D. in organic Chemistry from Northeastern University and a BS in Biochemistry from Suffolk University. Prior to his election to the Board of Directors, Mr. Humora served on DCAT’s Advisory Council for three years and was elected to the Leadership Development Committee from 2013 to 2015.
Kerri McCullough Wood
Senior Vice President and Head of Commercial
Teva API, Inc.
Kerri McCullough Wood is currently Senior Vice President and Head of Commercial, TAPI, (Teva Active Pharmaceutical Ingredients). Kerri’s responsibilities include global responsibility for all commercial aspects of TAPI’s business, primarily, sales, marketing and customer experience activities. In 2016, TAPI reported growth in revenue to $777M, across a customer base of more than 1,000 organizations across the globe. Until her recent promotion, Kerri was Vice President, Head of TAPI Global Sales. Prior to that, Kerri held roles of increasing and varied responsibility in sales and marketing at Teva for the last 17 years.
Kerri earned a Master’s Degree in Business Administration from Fairleigh Dickinson University and holds a Bachelor’s Degree in Science from Boston College. Previously, Kerri served as the Chair of the Education Committee for DCAT.
Vice President, CMC Development
Mr. Zook is the vice president of CMC development at Neurocrine Biosciences, Inc. in San Diego, California, where he is responsible for manufacturing small molecule, peptide and biologic APIs, including sterile manufacturing.
Mr. Zook has over 22 years of pharmaceutical research and chemical development experience contributing to 22 INDs/CTAs/IMPDs and two eCTD NDA submissions. He is responsible for over 32 different technical transfers to global manufacturing contractors and big Pharma partners, 14 publications and eight US patents on synthesis, continuous processing and polymorphism. In addition, Mr. Zook is experienced in leading/overseeing domestic and overseas PAI inspection activities, compliance and is highly trained in ICH & cGMP guidelines.
Dr. Folker Ruchatz
Corporate Vice President Product Supply and Lifecycle Management Human Pharma
Boehringer Ingelheim GmbH
Dr. Ruchatz is the Vice President of Corporate Product Supply and Lifecycle Management Human Pharma at Boehringer Ingelheim GmbH. He is responsible for the product supply and the portfolio/lifecycle management of Boehringer Ingelheim’s Corporate Division Human Pharma Supply and Global Quality. Previously he was responsible for the company’s external network of suppliers and all operations for consumer health care products. Joining the company in 2013, he first served as senior vice president of the contract manufacturing business biopharmaceuticals where he led new business strategies resulting in strong and profitable growth for the division. His prior work experience was at BASF Corporation. During that time, he was vice president of global business development customer synthesis and vice president of pharma solutions and dietary supplements.
Dr. Ruchatz has served as a member of DCAT’s Executive Committee since 2011. He was also a board member of the European Fine Chemical Group and Chairman of its Global Steering Committee of EXCiPACT.
Chief Operating Officer
Mr. Svokos is chief operating officer at AMRI which he joined in 2014. During the years 1989 to 2014, he served in various positions for Teva USA, most recently as the senior vice president of portfolio selection, launch and business development. He also held various operational, business development and sales and marketing roles, including president of Teva API.
Mr. Svokos received his B.S. in Chemical Engineering in 1980 from Columbia University and his M.B.A. from the University of Missouri in 1995.
Margaret M. Timony
Ms. Timony currently serves as the executive director of the Drug, Chemical & Associated Technologies Association (DCAT). Ms. Timony joined DCAT in December of 1998 after the organization moved its headquarters from New York to New Jersey. During her tenure, she has been responsible for overseeing the strategic direction and operations for the global business development association with 100+ active volunteers and a staff of 10.
Prior to this, Ms. Timony was the executive director of the American Physical Therapy Association of New Jersey (APTAnj) where she was responsible for the management and operations of the 2,500 member professional society which included legislative and regulatory advocacy. During her tenure at APTAnj, she also served concurrently as the executive director of the Acute Care practice section and the Research section for the national APTA organization.
A graduate of Widener University, she is active in association management professional societies and served as a board member and past president of the Middle Atlantic Society of Association Executives. She is also a member of the American Society of Association Executives and has led several small-staffed association group forums and committees.
The Drug, Chemical & Associated Technologies Association (DCAT) is a not-for-profit, global business development association whose unique membership model integrates both innovator and generic drug manufacturers and suppliers of ingredients, development and manufacturing services, and related technologies. We are committed to provide programs, events and services that help our members meet their business objectives, expand their network of customers and suppliers, and gain insight into industry trends, markets, and those issues impacting pharmaceutical development and manufacturing.